标题
SEOM clinical guidelines in early stage breast cancer (2018)
作者
关键词
Early breast cancer, Adjuvant, Neoadjuvant, Genomic predictive test, Follow-up
出版物
Clinical & Translational Oncology
Volume 21, Issue 1, Pages 18-30
出版商
Springer Nature
发表日期
2018-11-15
DOI
10.1007/s12094-018-1973-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
- (2018) Anne-Vibeke Lænkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
- (2018) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
- (2018) Ivana Sestak et al. JAMA Oncology
- PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
- (2018) Helena Margaret Earl et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials
- (2017) Akina Natori et al. EUROPEAN JOURNAL OF CANCER
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
- (2017) Sukhbinder Dhesy-Thind et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
- (2017) Marloes G M Derks et al. LANCET ONCOLOGY
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardio-Onco-Hematología en la práctica clínica. Documento de consenso y recomendaciones
- (2017) Teresa López-Fernández et al. REVISTA ESPANOLA DE CARDIOLOGIA
- 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging
- (2017) Ana Paula Caresia Aroztegui et al. TUMOR BIOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
- (2017) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
- (2016) X. Li et al. CLINICAL CANCER RESEARCH
- West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
- (2016) Oleg Gluz et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
- (2016) Martine Piccart-Gebhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
- (2016) Richard Buus et al. JNCI-Journal of the National Cancer Institute
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
- (2016) Michael Untch et al. LANCET ONCOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
- (2016) Richard Buus et al. JNCI-Journal of the National Cancer Institute
- Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: value added or just cost?
- (2015) Raphael J. Louie et al. BREAST CANCER RESEARCH AND TREATMENT
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
- (2015) Carolyn D. Runowicz et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
- (2015) A. Prat et al. CLINICAL CANCER RESEARCH
- The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis
- (2015) T.J.A. van Nijnatten et al. EJSO
- Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment
- (2015) M. van der Heiden-van der Loo et al. EUROPEAN JOURNAL OF CANCER
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contralateral Prophylactic Mastectomy After Unilateral Breast Cancer
- (2014) Oluwadamilola Motunaryo Fayanju et al. ANNALS OF SURGERY
- Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment
- (2014) Andrew McBride et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline
- (2014) Thomas A. Buchholz et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
- (2014) Ines Vaz-Luis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
- (2014) Mila Donker et al. LANCET ONCOLOGY
- Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
- (2013) M. Gnant et al. ANNALS OF ONCOLOGY
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
- (2013) P Dubsky et al. BRITISH JOURNAL OF CANCER
- Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
- (2013) Kevin S. Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- An International Ki67 Reproducibility Study
- (2013) Mei-Yin C. Polley et al. JNCI-Journal of the National Cancer Institute
- Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
- (2012) E. Alba et al. ANNALS OF ONCOLOGY
- Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study
- (2012) Lawrence J. Solin et al. BREAST CANCER RESEARCH AND TREATMENT
- Personalized Medicine in Breast Cancer: A Systematic Review
- (2012) Sang-Hoon Cho et al. Journal of Breast Cancer
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
- (2011) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Local-Regional Recurrence With and Without Radiation Therapy After Neoadjuvant Chemotherapy and Mastectomy for Clinically Staged T3N0 Breast Cancer
- (2011) Himanshu Nagar et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
- (2010) Gunter von Minckwitz et al. BREAST CANCER RESEARCH AND TREATMENT
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
- (2010) Francesco Sardanelli et al. EUROPEAN JOURNAL OF CANCER
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
- (2010) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surgical guidelines for the management of breast cancer
- (2009) Association of Breast Surgery at EJSO
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
- (2008) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started